Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022
John A. Snowden(Sheffield Teaching Hospitals NHS Foundation Trust), Bénédicte Neven(Université Paris-Panthéon-Assas), Raffaella Greco(Vita-Salute San Raffaele University), Mohamad Mohty(Sorbonne Université), Isabel Sánchez‐Ortega(European Society for Blood and Marrow Transplantation), Harry Dolstra(Radboud University Nijmegen), Ibrahim Yakoub‐Agha(Inserm), Grzegorz Basak(Medical University of Warsaw), Christian Chabannon(Inserm), Zinaida Perić(University of Rijeka), Paolo Pedrazzoli(Policlinico San Matteo Fondazione), Arjan C. Lankester(Leiden University Medical Center), Rafael F. Duarte(Institut Català d'Oncologia), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Selim Corbacioglu(Unknown), Régis Peffault de Latour(Hôpital Saint-Louis), Rafael de la Cámara(Hospital Universitario de La Princesa), Nicolaus Kröger(Universität Hamburg), Bertram Glaß(Helios Hospital Berlin-Buch)
Cited by 378
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
|New England Journal of Medicine|2020|1.8k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k